Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review.
10.19746/j.cnki.issn.1009-2137.2020.06.050
- Author:
Jing-Yu HU
1
;
Yue-Ru JI
1
;
Li LIU
2
Author Information
1. Department of Hematology, The Second Affiliated Hospital of Air Force Military Medical University, Xi'an 710038, Shanxi Province, China.
2. Department of Hematology, The Second Affiliated Hospital of Air Force Military Medical University, Xi'an 710038, Shanxi Province, China,E-mail: liuli1@ medmail.com.cn.
- Publication Type:Review
- MeSH:
Enhancer of Zeste Homolog 2 Protein/genetics*;
Hematologic Neoplasms/genetics*;
Humans;
Neoplasms;
Oncogenes;
Research
- From:
Journal of Experimental Hematology
2020;28(6):2097-2012
- CountryChina
- Language:Chinese
-
Abstract:
Enhancer of zeste homolog 2(EZH2) is a histone methyltransferase which regulate gene expression through epigenetic machinery. The abnormal expression of EZH2 has been described in many cancer types. With in-depth study, it was found that EZH2 is involved in the occurrence and development in many kinds of malignant hematologic disease which may play a dual role of oncogenes and tumor suppressor genes. In recent years, the emergence of EZH2 inhibitors provide a new option for the future treatment of hematological malignancies. In this review, the expression and clinical significance of EZH2 in various of hematological tumors were summarized briefly.
